Extracellular Signal-Regulated Kinase Is a Target of Cyclooxygenase-1-Peroxisome Proliferator-Activated Receptor-δ Signaling in Epithelial Ovarian Cancer
Open Access
- 1 June 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 67 (11) , 5285-5292
Abstract
The underlying causes of epithelial ovarian cancer (EOC) are unclear, and treatment options for patients with advanced disease are limited. There is evidence that the use of nonsteroidal anti-inflammatory drugs is associated with decreased risk of developing EOC. Nonsteroidal anti-inflammatory drugs inhibit cyclooxygenase (COX)-1 and COX-2, which catalyze prostaglandin biosynthesis. We previously showed that mouse and human EOCs have increased levels of COX-1, but not COX-2, and a COX-1–selective inhibitor, SC-560, attenuates prostaglandin production and tumor growth. However, the downstream targets of COX-1 signaling in EOC are not yet known. To address this question, we evaluated peroxisome proliferator-activated receptor δ (PPARδ) expression and function in EOC. We found that EOC cells express high levels of PPARδ, and neutralizing PPARδ function reduces tumor growth in vivo. More interestingly, aspirin, a nonsteroidal anti-inflammatory drug that preferentially inhibits COX-1, compromises PPARδ function and cell growth by inhibiting extracellular signal-regulated kinases 1/2, members of the mitogen-activated protein kinase family. Our study, for the first time, shows that whereas PPARδ can be a target of COX-1, extracellular signal-regulated kinase is a potential target of PPARδ. The ability of aspirin to inhibit EOC growth in vivo is an exciting finding because of its low cost, lack of cardiovascular side effects, and availability. [Cancer Res 2007;67(11):5285–92]Keywords
All Related Versions
This publication has 45 references indexed in Scilit:
- Long-term aspirin use and colorectal cancer risk: a cohort study in SwedenBritish Journal of Cancer, 2006
- Cyclooxygenase-1 Is Overexpressed in Multiple Genetically Engineered Mouse Models of Epithelial Ovarian CancerCancer Research, 2006
- Transcriptional Repression of Peroxisome Proliferator-activated Receptor β/δ in Murine Keratinocytes by CCAAT/Enhancer-binding ProteinsJournal of Biological Chemistry, 2005
- Long-term Use of Aspirin and Nonsteroidal Anti-inflammatory Drugs and Risk of Colorectal CancerJAMA, 2005
- Peroxisome proliferator‐activated receptor δ as a molecular target to regulate lung cancer cell growthFEBS Letters, 2005
- Roles of peroxisome proliferator-activated receptor delta (PPARδ) in the control of fatty acid catabolism. A new target for the treatment of metabolic syndromeBiochimie, 2004
- PPARδ activation induces COX-2 gene expression and cell proliferation in human hepatocellular carcinoma cellsBiochemical and Biophysical Research Communications, 2003
- A Randomized Trial of Aspirin to Prevent Colorectal AdenomasNew England Journal of Medicine, 2003
- Peroxisome proliferator-activated receptor β expression in human breast epithelial cell lines of tumorigenic and non-tumorigenic originThe International Journal of Biochemistry & Cell Biology, 2002
- Critical roles of PPARβ/δ in keratinocyte response to inflammationGenes & Development, 2001